Peregrine Pharmaceuticals (NASDAQ:PPHM) is up nearly 20% and reached a 19-month high after the biopharmaceutical company said Wednesday that it will present data from three preclinical studies highlighting the immuno-oncology and anti-viral potential of phosphatidylserine (PS)-targeting antibodies. Results will be presented at two upcoming Keystone Symposia to be held March 9-13. Shares of Peregrine (NASDAQ:PPHM) are at $2.29, and earlier touched $2.37 – its highest price … Continue reading Peregrine Pharmaceuticals (NASDAQ:PPHM) Up 20% to 19-Month High; Agenus (NASDAQ:AGEN) Soars